Clinical Trials Logo

Filter by:
NCT ID: NCT00240500 Completed - Hepatitis B Clinical Trials

Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers

Start date: October 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00235391 Completed - Sickle Cell Disease Clinical Trials

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Start date: October 2005
Phase: Phase 3
Study type: Interventional

This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.

NCT ID: NCT00234546 Completed - Clinical trials for Cerebrovascular Accident

Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity

Start date: February 2003
Phase: Phase 4
Study type: Interventional

The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.

NCT ID: NCT00234091 Completed - HIV Infections Clinical Trials

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

Start date: April 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine when HIV infected children should begin taking anti-HIV medications in order to improve both patient quality of life and survival.

NCT ID: NCT00231699 Completed - Child Clinical Trials

A Comparison of Prevention of Hypothermia in Pediatric Patient Between Wrapping With Cotton and Plastic.

Start date: January 2004
Phase: N/A
Study type: Interventional

Hypothermia leads to increased morbidity and mortality. Heat loss mainly occurs during anesthesia and surgery. Therefore prevention of hypothermia in pediatric patients undergoing general anesthesia is very important. However, there is very little information about effectiveness of various insulating materials used in the operating room. Objective: To compare the effectiveness of cotton and plastic for prevent intraoperative hypothermia in pediatric patients.

NCT ID: NCT00228917 Completed - Hepatitis B Clinical Trials

Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children

Start date: June 16, 2005
Phase: Phase 3
Study type: Interventional

This study will be conducted in two stages. In the diphtheria, tetanus, pertussis (DTP) booster phase, subjects will receive a booster dose of Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix (active control) at 15 to 18 or 24 months in a single-blind manner so that the subjects' parents will not know which vaccine was administered to their child. In the Mencevax ACWY phase at 24-30 months, a dose of Mencevax ACWY will be given in an open manner to only those subjects who received less than 4 doses of Tritanrix-HepB/Hib-MenAC. No blood samples will be taken in this safety study.

NCT ID: NCT00223080 Completed - HIV Infection Clinical Trials

HIV Vaccine Trial in Thai Adults

Start date: October 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.

NCT ID: NCT00213057 Completed - HIV Infections Clinical Trials

Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand

Start date: June 2001
Phase: Phase 1
Study type: Interventional

The primary aims of the study were to assess the safety and acceptability of Carraguard applied vaginally prior to sexual intercourse for six months in both women and men; and to examine several dimensions of acceptability. Secondary aims were to gauge reactions to a non-contraceptive microbicide, to assess use dynamics among Thai couples and to observe preliminary indications of sexually transmitted infections and reproductive tract infections averted. The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women and men would find Carraguard acceptable.

NCT ID: NCT00213044 Completed - HIV Infections Clinical Trials

A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women

Start date: March 2003
Phase: Phase 1
Study type: Interventional

Randomized, controlled, double-blinded, cross-over trial of 60 HIV-infected women recruited from general medical clinics, family planning clinics, groups/organizations working with persons living with AIDS to assess product safety, effect on genital tract HIV shedding, and product acceptability with vaginal use of Carraguard gel among HIV-infected women. Women had to be abstinent or in a seroconcordant relationship with only one partner for the study period.

NCT ID: NCT00213031 Completed - HIV Infections Clinical Trials

Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide

Start date: February 2000
Phase: Phase 2
Study type: Interventional

The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months. Secondary aims were to gather preliminary data on Carraguard's effectiveness in preventing male-to-female transmission of HIV, and other STIs. The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women would find Carraguard acceptable. The study was not powered to determine effectiveness, but based on safety, acceptability and feasibility parameters, the outcome of the Phase 2 trial would enable a decision whether or not to proceed to a Phase 3 trial.